Jérémy Nigri (PhD), jeremy@cshl.edu **Birth date:** 04/20/1989 in France

1 Bungtown Road, Cold Spring Harbor, NY11724, USA. **Citizenship:** French

Education

2021 - present Postdoctoral Fellow at Cold Spring Harbor Laboratory (CSHL), Cold Spring Harbor, NY, USA.
Mentor: Dr. David A. Tuveson
Research focus: Crosstalk between neurons, cancer-associated fibroblasts and cancer cells in pancreatic ductal adenocarcinoma (PDAC)

2016 – 2020 Ph.D. at the Cancer Research Center of Marseille (CRCM), Marseille, France.
Advisor: Dr. Richard Tomasini
Thesis: Stroma/cancer cells crosstalk in PDAC following chemotherapy treatment.

2014 - 2016 Master's degree in Human Pathology, specialization in oncology, Aix-Marseille University, Marseille, France. Internship (8 months): "*PAP role in perineural invasion in pancreatic cancer*" & "*ANXA6 role in EVs uptake*", France, Marseille.

2010 - 2011 Bachelor's degree in the department of Physiology/Physiopathology, specialization in Pharmacology, Joseph Fourrier University, Grenoble, France. Internship (1 year): *"Validation of an automatic paradoxical sleep deprivation system for rats"*

2008 - 2010 Two-year technical degree in biological engineering, specialization in biological and biochemical analyses, Burgundy University, Dijon. Internship (6 months): *"Mutation in the gyrA gene is associated to resistant Arcobacter strains to quinolones", Spain, Valencia.*

Advanced Training & Workshops

2025 **Cancer Neuroscience Course**, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.

Honors and Fellowships

2025-2027: 2025 Pancreatic Cancer Action Network Fellowship funded by the Francois Wallace Fund in loving memory of Michael Insel

2019-2020: Awardee of the **Ligue Nationale Contre le Cancer (Foundation) scholarship** for the 4th year graduate students)

2018 : Laureate of Junior AFRCP grant: 5000€ for the research project

2016-2019: Awardee of the **French distinguished National scholarship** for graduate students

Presentations & Awards

2024 **Mechanisms & Models of Cancer**, USA, Boston (Poster).

2023 **Biology of Cancer: Microenvironment & Metastasis**, USA, Boston (Poster).

2023 **AACR Special Conference: Pancreatic Cancer**, USA, Boston (Poster)

2021 **French Society of Extracellular Vesicles PhD Award 2021.**

2019 ***Pancreatic Cancer Symposium***, France, Toulouse **(Laureate of the best oral communication award).**
French Society of Extracellular Vesicles**,** France, Nantes **(Laureate of the best cancer poster award).**
Annual Seminar of "Cancéropôle de Provence-Alpes-Côte d'Azur", France, Saint-Raphaël **(Laureate of the best translational research/ clinical poster award).**
CFP meeting (Club Français du Pancréas) France, Lyon **(Laureate of the CFP research gratification award).**

2018 ***International Cancer Symposium of the CRCL***, France, Lyon.
Annual Seminar of Life and health sciences doctoral school, France, Marseille (**Poster**).
ISEV (International Society for Extracellular Vesicles), Spain, Barcelona (**Poster**).
AFRCP day, France, Clichy (Oral communication).

2016 ***CFP meeting*** (Club Français du Pancréas), France, Marseille.
AFRCP day, France, Marseille (Poster).
EPC (European Pancreatic Club), United Kingdom, Liverpool.

2015 ***CFP meeting*** (Club Français du Pancréas), France, Toulouse (**Laureate of Mayoly Spindler award for the best oral communication**).
Pancreatic Cancer Symposium, France, Marseille (Poster).

2014 ***CFP meeting*** (Club Français du Pancréas), France, Paris.
AFRCP day, France, Paris (Poster).

Professional experiences

2013 - 2016 Ethics committee member of the Marseille division (CE2A-14).

2012 - 2016 Engineer at INSERM U1068, Pancreatic Cancer team. Expertise in in vivo preclinical studies.

Lab Manager worked on *in vivo* experiments and associated techniques (in vitro, ex vivo, IHC) for Dr. Tomasini group.

Student Mentorship

2016 & 2018 (6 months each), mentored three 1st and 2nd year-masters students**.**

Publications

- **Two first author publications**
  1) **Nigri J** *et al.*, CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. **Science Signaling**. 2022 Aug 2;15(745):eabg819
  2) **Nigri J et al.,** PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. **Cell Mol Life Sci**. 2017 Nov;74(22):4231-4243.

- **Second author publications, related to my work as a collaborator.**
  3) Rapetti-Mauss R, **Nigri J** *et al*., *SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer.* **Gut**, 2022 Published Online First: 01 September 2022.
  4) Hussain Z, Nigri J and Tomasini T, *The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer*. Cancers. 2021 Jun 18; 13(12), 3040.
  5) Morfoisse F*, De Toni F*, **Nigri J** et al., Coordinating Effect of VEGFC and Oleic Acid Participates to Tumor Lymphangiogenesis. **Cancers.** 2021 Jun 8; 13(12), 2851.
  6) Goehrig D, **Nigri J** *et al.*, *Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer.* **Gut**. 2018 Nov 10. pii:gutjnl-2018-31757
  7) Thakur AK, **Nigri J** *et al.*, *TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.* **Cell Death Differ**. 2016 Aug;23(8):1358-70.

- **Other publications with an intermediate position related to my work as a collaborator:**
  8) Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, **Nigri J** *et al*., *Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.* **Embo J.** 2022 May 2;41(9):e110466

  9) Samain R, Brunel A, Douché T, Fanjul M, Cassant-Sourdy S, Rochotte J, Cros J, Neuzillet C, Raffenne J, Duluc C, Perraud A, **Nigri J** *et al*., *Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages.* **Cell Mol Gastroenterol Hepatol.** 2021 Jan 20;11(5):1405-1436.

  10) Collignon A, Silvy F, Robert S, Trad M, Germain S, **Nigri J** *et al., Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma.* **Oncoimmunology**. 2018 Sep 25;7(12):e1504727.

  11) Bressy C, Lac S, **Nigri J** *et al., LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. **Cancer Res**. 2018 Feb 15;78(4):909-921.*

  12) Leca J, Martinez S, Lac S, **Nigri J** *et al., Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. **J Clin Invest**. 2016 Nov 1;126(11):4140-4156.*

  13) Ligat L, Saint-Laurent N, El-Mrani A, Gigoux V, Al Saati T, Tomasini R, **Nigri J** *et al., Pancreaticpreneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models. **Br J Cancer**. 2015 Dec 1;113(11):1590-8.*

  14) Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, Pinault M, Guimaraes C, **Nigri J** *et al., Cholesterol uptake disruption, in association with*

chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. ***Proc Natl Acad Sci U S A****. 2015 Feb 24;112(8):2473-8. doi: 10.1073/pnas.1421601112. Epub 2015 Feb 9.*

15) Secq V, Leca J, Bressy C, Guillaumond F, Skrobuk P, **Nigri J** *et al., Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.* ***Cell Death Dis****. 2015 Jan 15;6:e1592.*

16) Tomasini R, Secq V, Pouyet L, Thakur AK, Wilhelm M, **Nigri J** *et al., TAp73 is required for macrophage-mediated innate immunity and the resolution of inflammatory responses.* ***Cell Death Differ****. 2013 Feb;20(2):293-301.*

Patents

-New strategy targeting stroma/tumor cell crosstalk to treat cancer (EP2106624.4). 11/2021
-Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma (EP173054396). 04/2017. (PAP)
-Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling (EP173052937). 03/2017. (LIF)

References

Dr. David Tuveson (dtuveson@cshl.edu), Cold Spring Harbor Laboratory, Cold Spring Harbor, USA.
Dr. Richard Tomasini (richard.tomasini@inserm.fr), Cancer Research Center of Marseille, Marseille, France.
Dr. Damien Gervasoni (damien.gervasoni@cnrs.fr), Lyon Neuroscience Research Center, Lyon, France.
Dr. Sophie Vasseur (sophie.vasseur@inserm.fr), Cancer Research Center of Marseille, Marseille, France.
Dr. Fabienne Guillaumond (fabienne.guillaumond@inserm.fr) Cancer Research Center of Marseille, Marseille, France.

BIBLIOGRAPHY

Rapetti-Mauss, R., **Nigri, J.***, Berenguier, C.*, Finetti, P., Tubiana, S.S., Labrum, B., Allegrini, B., Pellissier, B., Efthymiou, G., Hussain, Z., Bousquet, C., Dusetti, N., Bertucci, F., Guizouarn, H., Melnyk, P., Borgese, F., Tomasini, R., Soriani, O., **2022**. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. **Gut** gutjnl-2021-326610. https://doi.org/10.1136/gutjnl-2021-326610

Nigri, J., Leca, J., Tubiana, S.-S., Finetti, P., Guillaumond, F., Martinez, S., Lac, S., Iovanna, J.L., Audebert, S., Camoin, L., Vasseur, S., Bertucci, F., Tomasini, R., **2022**. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. **Sci. Signal.** 15, eabg8191. https://doi.org/10.1126/scisignal.abg8191

Gouirand, V., Gicquel, T., Lien, E.C., Jaune-Pons, E., Da Costa, Q., Finetti, P., Metay, E., Duluc, C., Mayers, J.R., Audebert, S., Camoin, L., Borge, L., Rubis, M., Leca, J., **Nigri, J.**, Bertucci, F., Dusetti, N., Iovanna, J.L., Tomasini, R., Bidaut, G., Guillaumond, F., Vander Heiden, M.G., Vasseur, S., **2022**. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. **EMBO J.** 41, e110466. https://doi.org/10.15252/embj.2021110466

Guillot, J.*, Dominici, C.*, Lucchesi, A.*, Nguyen, H.T.T.*, Puget, A., Hocine, M., Rangel-Sosa, M.M., Simic, M., **Nigri, J.**, Guillaumond, F., Bigonnet, M., Dusetti, N., Perrot, J., Lopez, J., Etzerodt, A., Lawrence, T., Pudlo, P., Hubert, F., Scoazec, J.-Y., van de Pavert, S.A., Tomasini, R., Chauvet, S., Mann, F., **2022**. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. **Nat. Commun.** 13, 1985. https://doi.org/10.1038/s41467-022-29659-w

Hussain, Z., **Nigri, J.**, Tomasini, R., **2021**. The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. **Cancers** 13, 3040. https://doi.org/10.3390/cancers13123040

Morfoisse, F.*, De Toni, F.*, **Nigri, J.**, Hosseini, M., Zamora, A., Tatin, F., Pujol, F., Sarry, J.-E., Langin, D., Lacazette, E., Prats, A.-C., Tomasini, R., Galitzky, J., Bouloumié, A., Garmy-Susini, B., **2021**. Coordinating Effect of VEGFC and Oleic Acid Participates to Tumor Lymphangiogenesis**.** **Cancers** 13, 2851. https://doi.org/10.3390/cancers13122851

Samain, R., Brunel, A., Douché, T., Fanjul, M., Cassant-Sourdy, S., Rochotte, J., Cros, J., Neuzillet, C., Raffenne, J., Duluc, C., Perraud, A., **Nigri, J.**, Gigoux, V., Bieche, I., Ponzo, M., Carpentier, G., Cascone, I., Tomasini, R., Schmid, H.A., Mathonnet, M., Nicolle, R., Bousquet, M.-P., Martineau, Y., Pyronnet, S., Jean, C., Bousquet, C., **2021**. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. **Cell. Mol. Gastroenterol. Hepatol.** 11, 1405–1436. https://doi.org/10.1016/j.jcmgh.2021.01.008

Goehrig, D., **Nigri, J.**, Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., Curto, R., Hervieu, V., de La Fouchardière, C., Novelli, F., Milani, P., Tomasini, R., Bousquet, C., Bertolino, P., Hennino, A., **2019**. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. **Gut** 68, 693–707. https://doi.org/10.1136/gutjnl-2018-317570

Collignon, A., Silvy, F., Robert, S., Trad, M., Germain, S., **Nigri, J.**, André, F., Rigot, V., Tomasini, R., Bonnotte, B., Lombardo, D., Mas, E., Beraud, E., **2018**. Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. **Oncoimmunology** 7, e1504727. https://doi.org/10.1080/2162402X.2018.1504727

Bressy, C., Lac, S., **Nigri, J.**, Leca, J., Roques, J., Lavaut, M.-N., Secq, V., Guillaumond, F., Bui, T.-T., Pietrasz, D., Granjeaud, S., Bachet, J.-B., Ouaissi, M., Iovanna, J., Vasseur, S., Tomasini, R., **2018**. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. **Cancer Res.** 78, 909–921. https://doi.org/10.1158/0008-5472.CAN-15-2790

Nigri, J., Gironella, M., Bressy, C., Vila-Navarro, E., Roques, J., Lac, S., Bontemps, C., Kozaczyk, C., Cros, J., Pietrasz, D., Maréchal, R., Van Laethem, J.-L., Iovanna, J., Bachet, J.-B., Folch-Puy, E., Tomasini, R., **2017**. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. **Cell. Mol. Life Sci.** CMLS 74, 4231–4243. https://doi.org/10.1007/s00018-017-2579-9

Leca, J., Martinez, S., Lac, S., **Nigri, J.**, Secq, V., Rubis, M., Bressy, C., Sergé, A., Lavaut, M.-N., Dusetti, N., Loncle, C., Roques, J., Pietrasz, D., Bousquet, C., Garcia, S., Granjeaud, S., Ouaissi, M., Bachet, J.B., Brun, C., Iovanna, J.L., Zimmermann, P., Vasseur, S., Tomasini, R., **2016**. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. **J. Clin. Invest.** 126, 4140–4156. https://doi.org/10.1172/JCI87734

Thakur, A.K., **Nigri, J.**, Lac, S., Leca, J., Bressy, C., Berthezene, P., Bartholin, L., Chan, P., Calvo, E., Iovanna, J.L., Vasseur, S., Guillaumond, F., Tomasini, R., **2016**. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. **Cell Death Differ.** 23, 1358–1370. https://doi.org/10.1038/cdd.2016.18

Ligat, L., Saint-Laurent, N., El-Mrani, A., Gigoux, V., Al Saati, T., Tomasini, R., **Nigri, J.**, Dejean, S., Pont, F., Baer, R., Guillermet-Guibert, J., Cordelier, P., Lopez, F., Dufresne, M., **2015**. Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models. **Br. J. Cancer** 113, 1590–1598. https://doi.org/10.1038/bjc.2015.370

Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., Pinault, M., Guimaraes, C., **Nigri, J.**, Loncle, C., Lavaut, M.-N., Garcia, S., Tailleux, A., Staels, B., Calvo, E., Tomasini, R., Iovanna, J.L., Vasseur, S., **2015**. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. **Proc. Natl. Acad. Sci. U. S. A.** 112, 2473–2478. https://doi.org/10.1073/pnas.1421601112